Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines

Federica Mazzuca, Concetta Elisa Onesti, Michela Roberto, Marco Di Girolamo, Andrea Botticelli, Paola Begini, Lidia Strigari, Paolo Marchetti, Maurizio Muscaritoli

Research output: Contribution to journalReview article

Abstract

Background: Sarcopenia refers to the reduction of both volume and number of skeletal muscle fibers. Lean body mass loss is associated with survival, quality of life and tolerance to treatment in cancer patients. The aim of our study is to analyse the association between toxicities and sarcopenia in early breast cancer patients receiving adjuvant treatment. Materials and Methods: Breast cancer patients who have received anthracyclinebased adjuvant treatment were retrospectively enrolled. CT scan images performed before, during and after adjuvant chemotherapy were used to evaluate lean body mass at third lumbar vertebra level with the software Slice Omatic V 5.0. Results: 21 stage I-III breast cancer patients were enrolled. According to the skeletal muscle index at third lumbar vertebra cut-off =38.5 cm2/m2, 8 patients (38.1%) were classified as sarcopenic before starting treatment, while 10 patients (47.6%) were sarcopenic at the end of treatment. A lower baseline L3 skeletal muscle index is associated with G3-4 vs G0-2 toxicities (33.4 cm2/m2 (31.1-39.9) vs 40.5 cm2/m2 (33.4-52.0), p = 0.028). Similarly skeletal muscle cross sectional area was significantly lower in patients with G3-4 toxicities (86.7 cm2 (82.6-104.7) vs 109.0 cm2 (83.3-143.9), p = 0.017). L3 skeletal muscle index is an independent predictor of severe toxicity (p = 0.0282) in multivariate analysis. Conclusion: Lean body mass loss is associated with higher grade of toxicity in early breast cancer patients receiving adjuvant chemotherapy.

Original languageEnglish
Pages (from-to)25714-25722
Number of pages9
JournalOncotarget
Volume9
Issue number39
DOIs
Publication statusPublished - May 22 2018

Keywords

  • Adjuvant chemotherapy
  • Anthracyclines toxicity
  • Breast cancer
  • Lean body mass
  • Sarcopenia

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines'. Together they form a unique fingerprint.

  • Cite this

    Mazzuca, F., Onesti, C. E., Roberto, M., Di Girolamo, M., Botticelli, A., Begini, P., Strigari, L., Marchetti, P., & Muscaritoli, M. (2018). Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines. Oncotarget, 9(39), 25714-25722. https://doi.org/10.18632/oncotarget.25394